{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:49:49Z","timestamp":1777452589757,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (C\n                      <jats:sub>min<\/jats:sub>\n                      ) values contribute to virological outcomes during DRV\/ritonavir monotherapy (mtDRV\/rtv).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple therapy switched to mtDRV\/rtv (800\/100 mg every 24 h). Previous virological failures (VF) on protease-inhibitor-based regimens were allowed if the historical resistance tests showed no major resistance mutation to DRV\/rtv. VF was defined as two consecutive HIV RNA measurements of &gt;200 copies\/ml. Efficacy was analysed by per-protocol and by intention-to-treat analyses. Plasma DRV C\n                      <jats:sub>min<\/jats:sub>\n                      values were measured by LC-MS\/MS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 150 subjects were included. At week 96, the efficacy rate on treatment was 83.6% (95% CI 77.2%, 90.0%) by per-protocol analysis and 67.6% (95% CI 60.0%, 75.2%) by intention-to-treat. In the whole cohort the median (IQR) DRV C\n                      <jats:sub>min<\/jats:sub>\n                      was significantly higher during the periods of undetectable than of detectable viraemia (1.82 \u03bcg\/ml [1.47\u20132.46] versus 1.56 \u03bcg\/ml [0.93\u20132.32]; P=0.006) as well as in the subjects with blips and VF. However, a cutoff point sufficiently sensitive and specific could not be found.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The DRV C\n                      <jats:sub>min<\/jats:sub>\n                      values are related to viral control during mtDRV\/rtv, but therapeutic drug monitoring cannot be recommended routinely as a precise cutoff point is unknown. Adherence is a key success factor on this regimen.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2722","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T09:04:45Z","timestamp":1389863085000},"page":"443-447","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Darunavir Minimum Plasma Concentration and Ritonavir-Boosted Darunavir Monotherapy Outcome in HIV-Infected Patients"],"prefix":"10.1177","volume":"19","author":[{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"first","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Torres-Cornejo","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar J","family":"BenMarzouk-Hidalgo","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ruiz-Valderas","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Lluch","sequence":"additional","affiliation":[{"name":"Farmacia Hospitalaria, Hospital Universitario Virgen del Rocio, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Rocio, Sevilla, Spain"},{"name":"Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"key":"bibr1-IMP2722","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"bibr2-IMP2722","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2013. (Updated 12 February 2013. Accessed 27 March 2013.) Available from http:\/\/www.aidsinfo.nih.gov\/contentfiles\/lvguidelines\/."},{"key":"bibr3-IMP2722","unstructured":"European AIDS Clinical Society. European guidelines for treatment of HIV infected adults in Europe. Version 7.0 (Updated 1 October 2013. Accessed 27 October 2013.) Available from http:\/\/eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf."},{"key":"bibr4-IMP2722","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2012.03.007"},{"issue":"2","key":"bibr5-IMP2722","first-page":"1","volume":"13","author":"Williams I.","year":"2012","journal-title":"HIV Med"},{"key":"bibr6-IMP2722","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1710"},{"key":"bibr7-IMP2722","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks052"},{"key":"bibr8-IMP2722","unstructured":"Prezista (darunavir). Full prescribing information. Janssen-Cilag SpA, Latina, Italy. European Medicine Agency. (Updated 30 October 2013. Accessed 23 November 2013.) Available from http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000707\/WC500041756.pdf."},{"key":"bibr9-IMP2722","unstructured":"Sekar V., De Meyer S., Vangeneugden T. Pharmacokinetic\/pharmacodynamic (PK\/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-experienced HIV-infected patients.\n                      13th Conference on Retroviruses and Opportunistic Infections\n                      , 5\u20139 February 2006, Denver, CO, USA. Abstract 239b."},{"key":"bibr10-IMP2722","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00520-08"},{"issue":"4","key":"bibr11-IMP2722","first-page":"18338","volume":"15","author":"Kakuda T.","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"bibr12-IMP2722","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq295"},{"key":"bibr13-IMP2722","doi-asserted-by":"publisher","DOI":"10.1310\/hct0906-418"},{"key":"bibr14-IMP2722","first-page":"266","volume":"16","author":"Hirsch M.S.","year":"2008","journal-title":"Top HIV Med"},{"key":"bibr15-IMP2722","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.01.008"},{"key":"bibr16-IMP2722","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-100"},{"key":"bibr17-IMP2722","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.02.057"},{"key":"bibr18-IMP2722","doi-asserted-by":"publisher","DOI":"10.1310\/hct0904-238"},{"key":"bibr19-IMP2722","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir518"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:51:52Z","timestamp":1777380712000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.3851\/IMP2722"],"URL":"https:\/\/doi.org\/10.3851\/imp2722","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,1]]}}}